Exploring the Management of Statin Intolerant Patients: 2016 and Beyond

被引:8
作者
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Karagiannis, Asterios [1 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece
关键词
Statins; intolerance; muscle symptoms; transaminases; creatine kinase; new-onset diabetes; side effects; ezetimibe; proprotein convertase subtilisin kexin 9 inhibitors; non-statin lipid-lowering drugs; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; FATTY LIVER-DISEASE; BILE-ACID SEQUESTRANTS; CHRONIC KIDNEY-DISEASE; C-REACTIVE PROTEIN; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; VITAMIN-D LEVELS; CARDIOVASCULAR-DISEASE; DOUBLE-BLIND;
D O I
10.2174/1570161114666160226150028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins remain the cornerstone of lipid-lowering treatment. They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing every-other- day or once weekly may be another option. Several non-statin lipid-lowering drugs (ezetimibe, fibrates, colesevelam, niacin or proprotein convertase subtilisin kexin-9 inhibitors) are available as monotherapy or in combination with statins to achieve efficacy and tolerability.
引用
收藏
页码:523 / 533
页数:11
相关论文
共 50 条
  • [31] Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia
    Gagnon, Charles A.
    Ashraf, Ambika P.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (11) : 617 - 628
  • [32] Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (15) : 1673 - 1677
  • [33] Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
    Moriarty, Patrick M.
    Jacobson, Terry A.
    Bruckert, Eric
    Thompson, Paul D.
    Guyton, John R.
    Baccara-Dinet, Marie T.
    Gipe, Daniel
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) : 554 - 561
  • [34] Approach to Statin Use in 2016: an Update
    Miller, P. Elliott
    Martin, Seth S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (05)
  • [35] Total lipid management and residual risk: beyond statin therapy
    Evans, Marc
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (03) : 132 - 136
  • [36] Evidence-Based Management of Statin Myopathy
    Charles R. Harper
    Terry A. Jacobson
    Current Atherosclerosis Reports, 2010, 12 : 322 - 330
  • [37] Evidence-Based Management of Statin Myopathy
    Harper, Charles R.
    Jacobson, Terry A.
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) : 322 - 330
  • [38] Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
    Tomlinson, Brian
    Chan, Paul
    Zhang, Yuzhen
    Lam, Christopher Wai Kei
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2137 - 2151
  • [39] Management of dyslipidemia in HIV-infected patients
    Malvestutto, Carlos D.
    Aberg, Judith A.
    CLINICAL LIPIDOLOGY, 2011, 6 (04) : 447 - 462
  • [40] Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials
    Angelopoulos, John
    Krassakopoulos, Nickolaos
    Nathanson, Robin
    Boukas, Stella
    Sampalis, John S.
    ARCHIVES OF MEDICAL SCIENCE, 2009, 5 (03) : 347 - 363